108 related articles for article (PubMed ID: 16256959)
1. CB1 receptor knockout mice show similar behavioral modifications to wild-type mice when enkephalin catabolism is inhibited.
Jardinaud F; Crété D; Canestrelli C; Ledent C; Roques BP; Noble F
Brain Res; 2005 Nov; 1063(1):77-83. PubMed ID: 16256959
[TBL] [Abstract][Full Text] [Related]
2. Facilitation of enkephalins-induced delta-opioid behavioral responses by chronic amisulpride treatment.
Cordonnier L; Sanchez M; Roques BP; Noble F
Neuroscience; 2005; 135(1):1-10. PubMed ID: 16084652
[TBL] [Abstract][Full Text] [Related]
3. Physiological control of emotion-related behaviors by endogenous enkephalins involves essentially the delta opioid receptors.
Nieto MM; Guen SL; Kieffer BL; Roques BP; Noble F
Neuroscience; 2005; 135(2):305-13. PubMed ID: 16112476
[TBL] [Abstract][Full Text] [Related]
4. Kappa- and delta-opioid receptor functional activities are increased in the caudate putamen of cannabinoid CB1 receptor knockout mice.
Urigüen L; Berrendero F; Ledent C; Maldonado R; Manzanares J
Eur J Neurosci; 2005 Oct; 22(8):2106-10. PubMed ID: 16262648
[TBL] [Abstract][Full Text] [Related]
5. Cannabinoid CB1 receptors of the rat central amygdala mediate anxiety-like behavior: interaction with the opioid system.
Zarrindast MR; Sarahroodi S; Arzi A; Khodayar MJ; Taheri-Shalmani S; Rezayof A
Behav Pharmacol; 2008 Oct; 19(7):716-23. PubMed ID: 18797248
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the enkephalin-metabolizing enzymes by the first systemically active mixed inhibitor prodrug RB 101 induces potent analgesic responses in mice and rats.
Noble F; Soleilhac JM; Soroca-Lucas E; Turcaud S; Fournie-Zaluski MC; Roques BP
J Pharmacol Exp Ther; 1992 Apr; 261(1):181-90. PubMed ID: 1560364
[TBL] [Abstract][Full Text] [Related]
7. CB1 cannabinoid receptor modulates 3,4-methylenedioxymethamphetamine acute responses and reinforcement.
Touriño C; Ledent C; Maldonado R; Valverde O
Biol Psychiatry; 2008 Jun; 63(11):1030-8. PubMed ID: 17950256
[TBL] [Abstract][Full Text] [Related]
8. Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain.
Sain NM; Liang A; Kane SA; Urban MO
Neuropharmacology; 2009 Sep; 57(3):235-41. PubMed ID: 19538975
[TBL] [Abstract][Full Text] [Related]
9. Expression of opioid receptors and c-fos in CB1 knockout mice exposed to neuropathic pain.
Pol O; Murtra P; Caracuel L; Valverde O; Puig MM; Maldonado R
Neuropharmacology; 2006 Jan; 50(1):123-32. PubMed ID: 16360182
[TBL] [Abstract][Full Text] [Related]
10. Interactions between the anxiogenic effects of CB1 gene disruption and 5-HT3 neurotransmission.
Mikics E; Vas J; Aliczki M; Halasz J; Haller J
Behav Pharmacol; 2009 May; 20(3):265-72. PubMed ID: 19421027
[TBL] [Abstract][Full Text] [Related]
11. [Characteristics of effects of mu-, delta-, and kappa-opioid agonists and enkephalinase inhibitor RB101 in rats of two inbred strains].
Sudakov SK; Liupina IuV; Medvedeva OF; Tiurina IV; Maldonado R
Biull Eksp Biol Med; 1998 May; 125(5):551-4. PubMed ID: 9644557
[No Abstract] [Full Text] [Related]
12. Differential regulation of morphine antinociceptive effects by endogenous enkephalinergic system in the forebrain of mice.
Chen TC; Cheng YY; Sun WZ; Shyu BC
Mol Pain; 2008 Sep; 4():41. PubMed ID: 18826595
[TBL] [Abstract][Full Text] [Related]
13. Facilitation of fear extinction by midbrain periaqueductal gray infusions of RB101(S), an inhibitor of enkephalin-degrading enzymes.
McNally GP
Behav Neurosci; 2005 Dec; 119(6):1672-7. PubMed ID: 16420170
[TBL] [Abstract][Full Text] [Related]
14. Involvement of CB1 cannabinoid receptors in emotional behaviour.
Martin M; Ledent C; Parmentier M; Maldonado R; Valverde O
Psychopharmacology (Berl); 2002 Feb; 159(4):379-87. PubMed ID: 11823890
[TBL] [Abstract][Full Text] [Related]
15. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
Whiteside GT; Gottshall SL; Boulet JM; Chaffer SM; Harrison JE; Pearson MS; Turchin PI; Mark L; Garrison AE; Valenzano KJ
Eur J Pharmacol; 2005 Dec; 528(1-3):65-72. PubMed ID: 16316650
[TBL] [Abstract][Full Text] [Related]
16. Behavioral effects of the novel cannabinoid full agonist AM 411.
McLaughlin PJ; Lu D; Winston KM; Thakur G; Swezey LA; Makriyannis A; Salamone JD
Pharmacol Biochem Behav; 2005 May; 81(1):78-88. PubMed ID: 15894067
[TBL] [Abstract][Full Text] [Related]
17. RB101-mediated protection of endogenous opioids: potential therapeutic utility?
Jutkiewicz EM
CNS Drug Rev; 2007; 13(2):192-205. PubMed ID: 17627672
[TBL] [Abstract][Full Text] [Related]
18. Altered gene expression and functional activity of opioid receptors in the cerebellum of CB1 cannabinoid receptor knockout mice after acute treatments with cannabinoids.
Páldyová E; Bereczki E; Sántha M; Wenger T; Borsodi A; Benyhe S
Acta Biol Hung; 2007; 58 Suppl():113-29. PubMed ID: 18297798
[TBL] [Abstract][Full Text] [Related]
19. Acute delta9-tetrahydrocannabinol exposure facilitates quinpirole-induced hyperlocomotion.
Gorriti MA; Ferrer B; del Arco I; Bermúdez-Silva FJ; de Diego Y; Fernandez-Espejo E; Navarro M; Rodríguez de Fonseca F
Pharmacol Biochem Behav; 2005 May; 81(1):71-7. PubMed ID: 15894066
[TBL] [Abstract][Full Text] [Related]
20. Control of hormonal stress reactivity by the endogenous opioid system.
Bilkei-Gorzo A; Racz I; Michel K; Mauer D; Zimmer A; Klingmüller D; Zimmer A
Psychoneuroendocrinology; 2008 May; 33(4):425-36. PubMed ID: 18280051
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
